Combining GLP ‐1 Receptor Agonists and Health‐Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real‐World Single‐Center Study
Authors' conclusion
GLP-1RAs were effective in the real-world treatment of paediatric obesity. HBLT appears to be essential to increase persistence and efficacy of GLP-1RAs.
Study context
- Population
- Patients aged 8–18 years with obesity receiving liraglutide, all offered multidisciplinary health behaviour and lifestyle treatment (HBLT)
- Participants
- 51 patients
- Exposure
- Liraglutide continuers vs discontinuers; Obesity medication (OM)-specific HBLT vs high-frequency (HF) HBLT
- Outcome
- Relative change in BMI
- Follow-up
- 9.7 ± 6.6 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Continuers
−6.7%
± 7.5%
Discontinuers
−0.7%
± 5.1%
P = 0.03
- BMI reduction ≥ 5%
- 37.3%
- BMI reduction ≥ 10%
- 13.7%
Observational data: associations, not effects.
Further findings
| Outcome | OM-HBLT | HF HBLT |
|---|---|---|
| BMI change by HBLT type | −6.9% ± 7.2% | −4.0% ± 6.6% |
Treatment course
- Continued liraglutide
- 39.2%
- Discontinued, mainly due to gastrointestinal symptoms
- 33.3%
- Switched to semaglutide or underwent surgery
- 27.4%
Continuation with combined HBLT and liraglutide
- Odds of continuation, combined HBLT and liraglutide
- OR 18.5 (95% CI 2.0-929.8, p < 0.01)
BMI change by HBLT type
- Greater BMI reduction by trend with OM-HBLT vs HF-HBLT
Original publication
Combining GLP ‐1 Receptor Agonists and Health‐Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real‐World Single‐Center Study. Pediatr Obes. Published 1 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →